Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Inclusion Criteria: * Have histologically or cytologically proven adenocarcinoma of the pancreas. * Patient's acceptance to have a core biopsy. * Presence of at least one measurable lesion. * Must not have metastatic disease. * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>20 mm with conventional techniques or as \>10 mm with spiral CT scan. See Section 10.1.2 for the evaluation of measurable disease. * Must have received last dose of stereotactic body radiotherapy no longer than 28 days prior to enrollment. * Must have received last dose of chemotherapy at least 14 days or longer prior to entry into the study. * Age \>18 years. * ECOG performance status 0-1. * Patient's blood, kidney and liver function must within normal limits * Must use an acceptable form of birth control while on study. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Currently is participating or has participated in a study using any investigational therapy within the past 28 days or is currently using an investigational device. * Major surgery 28 days prior to study entry excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement. * Used any systemic steroids, immunosuppressant medications and anti-neoplastic treatment in the past 14 days. * Prior treatment with immunoth…